Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study

Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study

ImportancePatients with EGFR mutations who have advanced-stage non-small cell lung cancer (NSCLC) already receive tyrosine kinase inhibitors (TKIs) as the standard first-line therapy. Notably, Yunnan is a regional high incidence area of lung cancer in the highlands with a high rate of rare EGFR muta...

Full description

Bibliographic Details
Main Authors: Yanping Lin, Long Chen, Rong Li, Xin Liu, Quan Li, Jingjing Cai, Yaxi Du, Guangqiang Zhao, Xiaoxiong Wang, Zhenghai Shen, Yedan Liao, Yang Chen, Lin Xie, Yongchun Zhou, Yunchao Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
lung cancer
non-small cell lung cancer
EGFR
TKI
uncommon mutation
Yunnan
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1156647/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1156647/full

Similar Items